Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07847671 | Fecal Microbiota Transplantation With QL1706 Plus Bevacizumab for Advanced HCC | not yet recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07844057 | First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma(FIRE-12) | not yet recruiting | Phase 2 | 86 | Annika KurreckOTHER | 1 | Sep 28, 2026 |
| clinicaltrials |
| NCT07835737 | Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 78 | West China HospitalOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT07836712 | Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer | not yet recruiting | Phase 2 | 46 | University of Southern CaliforniaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07829926 | Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer(LENTIG-HCC) | not yet recruiting | Phase 2 | 120 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07831330 | Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07827053 | Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 36 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07827807 | PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC(Pearl) | not yet recruiting | Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07540832 | A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC | not yet recruiting | Phase 1 / Phase 2 | 80 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07753824 | A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) | not yet recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07581405 | GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer | not yet recruiting | Phase 2 | 26 | University of Illinois at ChicagoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07175389 | JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | not yet recruiting | Phase 1 / Phase 2 | 10 | West China HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774247 | Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma(AB-TCZ) | not yet recruiting | Phase 2 | 51 | CHA UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07765433 | Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 / Phase 3 | 336 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07765667 | NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC(CRI-KEV) | not yet recruiting | Phase 2 | 100 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 288 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07748611 | SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial | not yet recruiting | Phase 2 | 125 | Northwestern UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749859 | SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07209215 | ctDNA-Informed Management of Early-Stage Rectal Cancer(ULTIMATE) | not yet recruiting | Phase 2 | 200 | University of California, DavisOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07729592 | Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) | not yet recruiting | Phase 1 / Phase 2 | 90 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07709767 | Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 21 | Tang-Du HospitalOTHER | 0 | Jul 17, 2026 | clinicaltrials |
| NCT07711067 | A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer(MATTERS-2) | not yet recruiting | Phase 2 / Phase 3 | 95 | ElmediXINDUSTRY | 2 | Jul 17, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705919 | DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07701681 | Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 | 75 | Sun Yat-sen UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07678593 | A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation | not yet recruiting | Phase 1 / Phase 2 | 222 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT07689292 | Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma(SKB264-Fru-GA) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 9, 2026 | clinicaltrials |
| NCT07691489 | A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer | not yet recruiting | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691632 | Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07621484 | HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer | not yet recruiting | Phase 2 | 48 | Shanghai Changzheng HospitalOTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07687914 | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 50 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07685704 | Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study | not yet recruiting | Phase 2 | 46 | Zhifeng Zhao, PhDOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07682454 | Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | not yet recruiting | Phase 2 | 50 | University of California, San FranciscoOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07658872 | Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | not yet recruiting | Phase 2 | 120 | Sichuan UniversityOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07655661 | Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. | not yet recruiting | Phase 2 | 52 | Ming LiuOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657273 | Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 20 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07644208 | PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07621562 | Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer | not yet recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07610629 | Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer(RA-A-NP) | not yet recruiting | Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | May 28, 2026 | clinicaltrials |
| NCT07495579 | Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)(REVIVE) | not yet recruiting | Phase 2 | 146 | Asan Medical CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07590336 | 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma(NYHCC) | not yet recruiting | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07584018 | The DoHAICs Study Expansion Phase | not yet recruiting | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
Data updated 19 hours agoSource updated Sep 29, 2026source: clinicaltrials